Comparative Pharmacology
Head-to-head clinical analysis: BRINEURA versus SUCRAID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRINEURA versus SUCRAID.
BRINEURA vs SUCRAID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BRINEURA (cerliponase alfa) is a recombinant human tripeptidyl peptidase-1 (TPP1) enzyme that replaces deficient TPP1 in patients with neuronal ceroid lipofuscinosis type 2 (CLN2 disease). It hydrolyzes tripeptides from the N-terminus of proteins, reducing accumulation of autofluorescent lipopigments in lysosomes.
SUCRAID (sacrosidase) is a yeast-derived enzyme that hydrolyzes sucrose into glucose and fructose, facilitating absorption in patients with congenital sucrase-isomaltase deficiency.
400 mg every 2 weeks via intravenous infusion over 1.5 hours.
Adults: 1 mL (5 mg/mL) as an oral drop taken with the first bite of each meal. Maximum 5 mL per meal.
None Documented
None Documented
Terminal half-life is approximately 3 to 4 days (mean 3.5 days) in pediatric patients, supporting weekly intravenous dosing.
Intravenous administration: terminal half-life approximately 2.6 hours. Clinical context: Sacrosidase acts locally in the small intestine; systemic absorption is minimal. The short half-life reflects rapid clearance from plasma but does not correlate with intraluminal activity.
Primarily catabolized via peptide hydrolysis to small peptides and amino acids; renal excretion of intact enzyme is negligible (<1% of dose).
Primarily renal (minimal, as the drug acts locally in the GI tract). Less than 2% of the absorbed dose is excreted unchanged in urine; the majority is metabolized locally and excreted in feces.
Category C
Category C
Enzyme Replacement
Enzyme Replacement